Barbara Sitek Selected Research

O(2)- vinyl- 1- (pyrrolidin- 1- yl)diazen- 1- ium- 1,2- diolate

6/2017	Differential effects of liver steatosis on pharmacokinetic profile of two closely related hepatoselective NO-donors; V-PYRRO/NO and V-PROLI/NO.
7/2015	Hepatoselective Nitric Oxide (NO) Donors, V-PYRRO/NO and V-PROLI/NO, in Nonalcoholic Fatty Liver Disease: A Comparison of Antisteatotic Effects with the Biotransformation and Pharmacokinetics.
2/2015	The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Barbara Sitek Research Topics

Disease

12	Neoplasms (Cancer) 10/2021 - 04/2009
12	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 01/2014
9	Fibrosis (Cirrhosis) 01/2019 - 04/2009
7	Inflammation (Inflammations) 11/2021 - 04/2009
6	Infections 01/2020 - 12/2013
5	Adenocarcinoma 05/2017 - 01/2008
4	Virus Diseases (Viral Diseases) 01/2022 - 01/2019
4	Hepatitis C 01/2019 - 04/2009
4	Cholangiocarcinoma 10/2017 - 07/2014
3	Carcinoma (Carcinomatosis) 01/2021 - 01/2012
3	Non-alcoholic Fatty Liver Disease 01/2020 - 07/2015
3	Liver Cirrhosis (Hepatic Cirrhosis) 01/2019 - 04/2009
3	Fatty Liver 06/2017 - 02/2015
2	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 01/2022
2	Neuroblastoma 10/2021 - 03/2005
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021 - 01/2008
2	Kidney Diseases (Kidney Disease) 01/2021 - 07/2008
2	Atherosclerosis 11/2019 - 11/2016
2	Atherosclerotic Plaque (Atheroma) 11/2019 - 02/2016
2	Thrombosis (Thrombus) 01/2018 - 11/2016
1	COVID-19 01/2022
1	Scrapie 01/2022
1	Asthma (Bronchial Asthma) 11/2021
1	Leukemia 01/2021
1	Cystitis 01/2021
1	Hemolytic-Uremic Syndrome 01/2021
1	Melanoma (Melanoma, Malignant) 01/2020
1	Bacterial Infections (Bacterial Infection) 01/2020
1	Chronic Hepatitis C 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Persistent Infection 01/2019
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2019
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019
1	Carcinoma in Situ 01/2019
1	Endotoxemia 01/2019
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2018
1	Liver Neoplasms (Liver Cancer) 12/2017
1	Pathologic Processes 12/2017

Drug/Important Bio-Agent (IBA)

21	Proteins (Proteins, Gene)FDA Link 01/2022 - 07/2008
20	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2009
18	ProteomeIBA 10/2022 - 03/2005
6	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2016
3	Biological ProductsIBA 01/2022 - 03/2005
3	InterferonsIBA 01/2022 - 12/2013
3	Apolipoproteins E (ApoE)IBA 11/2019 - 02/2016
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 07/2015
3	EnzymesIBA 12/2017 - 07/2008
3	O(2)- vinyl- 1- (pyrrolidin- 1- yl)diazen- 1- ium- 1,2- diolateIBA 06/2017 - 02/2015
2	Interleukin-6 (Interleukin 6)IBA 01/2020 - 09/2015
2	Triglycerides (Triacylglycerol)IBA 01/2020 - 02/2015
2	NitratesIBA 11/2019 - 02/2016
2	Superoxides (Superoxide)IBA 01/2019 - 01/2018
2	CollagenIBA 01/2018 - 05/2015
2	O2-vinyl 1- (2- (carboxylato)pyrrolidin- 1- yl)diazen- 1- ium- 1,2- diolateIBA 06/2017 - 07/2015
2	CeramidesIBA 01/2017 - 02/2015
2	CytokinesIBA 01/2017 - 09/2015
2	Concanavalin AIBA 12/2016 - 09/2015
2	Adenosine Triphosphate (ATP)IBA 11/2016 - 09/2015
2	microfibrillar proteinIBA 03/2016 - 05/2015
2	CholesterolIBA 02/2016 - 02/2015
2	HaptoglobinsIBA 02/2016 - 09/2015
2	Fatty Acids (Saturated Fatty Acids)IBA 07/2015 - 02/2015
2	Glucose (Dextrose)FDA LinkGeneric 07/2015 - 02/2015
2	Coloring Agents (Dyes)IBA 01/2015 - 01/2008
1	Activated-Leukocyte Cell Adhesion Molecule (Neurolin)IBA 10/2022
1	enzalutamideIBA 10/2022
1	Docetaxel (Taxotere)FDA Link 01/2022
1	AutoantibodiesIBA 01/2022
1	Interferon Type IIBA 01/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022
1	AmmoniaIBA 01/2022
1	IminesIBA 01/2022
1	Lamin Type A (Lamin A)IBA 10/2021
1	AntigensIBA 10/2021
1	HLA-DP Antigens (HLA-DP)IBA 01/2021
1	Shiga Toxin (Shigella Toxin)IBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	LipidsIBA 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	Perilipin-5IBA 01/2020
1	serum P-component (CIt)IBA 01/2020
1	InflammasomesIBA 01/2020
1	Granzymes (Granzyme)IBA 01/2020
1	Cetuximab (Erbitux)FDA Link 01/2020
1	Acetylcholine (Acetylcholine Chloride)FDA Link 11/2019
1	Thrombin FDA Link 11/2019
1	hydroxide ionIBA 01/2019
1	2-hydroxyethidiumIBA 01/2019
1	dihydroethidineIBA 01/2019
1	Ethidium (Ethidium Bromide)IBA 01/2019
1	LipopolysaccharidesIBA 01/2019
1	Programmed Cell Death 1 ReceptorIBA 01/2019
1	dihydroethidiumIBA 01/2018
1	Soluble Guanylyl CyclaseIBA 01/2018
1	Peptides (Polypeptides)IBA 12/2017
1	CarbonIBA 12/2017

Therapy/Procedure

9	Therapeutics 10/2022 - 11/2016
2	Castration 10/2022 - 01/2022
2	Immunotherapy 01/2021 - 01/2020
1	Intravesical Administration 01/2019